Investor Relations

2024-05-17
VOLUNTARY ANNOUNCEMENT - APPROVAL BY NMPA FOR A RANDOMIZED, DOUBLEBLIND, CONTROLLED PHASE III CLINICAL TRIAL OF IMM01 (TIMDARPACEPT) IN COMBINATION WITH AZACITIDINE
2024-05-07
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 April 2024
2024-04-29
Proxy Form for the Annual General Meeting to be held on May 28, 2024
2024-04-29
NOTICE OF THE ANNUAL GENERAL MEETING
2024-04-29
(1) 2023 WORK REPORT OF THE BOARD OF DIRECTORS; (2) 2023 WORK REPORT OF THE SUPERVISORY COMMITTEE; (3) 2023 ANNUAL REPORT; (4) 2023 FINAL FINANCIAL REPORT AND 2024 FINANCIAL BUDGET REPORT; (5) 2023 PROFIT DISTRIBUTION PLAN; (6) APPOINTMENT OF EXECUTIVE DI
2024-04-26
Annual Report 2023
2024-04-17
VOLUNTARY ANNOUNCEMENT - APPROVAL BY NMPA FOR THE PHASE III CLINICAL TRIAL PROTOCOL OF IMM01 (TIMDARPACEPT)
2024-04-08
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 March 2024
2024-03-25
ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023
2024-03-13
DATE OF BOARD MEETING
2024-03-06
VOLUNTARY ANNOUNCEMENT - UNUSUAL PRICE MOVEMENTS
2024-03-04
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 29 February 2024
2024-03-04
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
2024-03-01
(1) RESIGNATION OF EXECUTIVE DIRECTOR, CHIEF FINANCIAL OFFICER AND AUTHORIZED REPRESENTATIVE; (2) PROPOSED APPOINTMENT OF EXECUTIVE DIRECTOR; AND (3) APPOINTMENT OF AUTHORIZED REPRESENTATIVE
2024-02-20
Notification Letter and Reply Form to Non-registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications
2024-02-20
Notification Letter and Reply Form to Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications
2024-02-05
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 January 2024
2024-01-05
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 December 2023
2023-12-05
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 November 2023
2023-11-20
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE II CLINICAL TRIAL OF IMM2510 FOR THE TREATMENT OF ASPS
Total 42 123
0.093067s